Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 426

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 426
---
 par value, 198,000,000 shares authorized; 96,900,496   and 93,731,831 issued and outstanding at December 31, 2024 and 2023,    respectively

    10

    9

    Additional paid-in capital

    5,738,924

    5,304,623

    Accumulated other comprehensive (loss) income, net of tax

    (218
    )

    918

    Accumulated deficit

    (4,210,974
    )

    (4,446,213
    )

    Total stockholders’ equity

    1,527,742

    859,337

    Total liabilities and stockholders’ equity
     
    $
    3,963,173

    $
    3,264,576

See accompanying notes to consolidated financial statements.

F-4

Sarepta Therapeutics, Inc.

Consolidated Statements of Comprehensive Income (Loss)

(in thousands, except per share data)

    For the Year Ended December 31,

    2024

    2023

    2022

    Revenues:

    Products, net
     
    $
    1,787,960

    $
    1,144,876

    $
    843,769

    Collaboration and other

    114,019

    98,460

    89,244

    Total revenues

    1,901,979

    1,243,336

    933,013

    Cost and expenses:

    Cost of sales (excluding amortization of in-licensed rights)

    319,099

    150,343

    139,989

    Research and development

    804,522

    877,387

    877,090

    Selling, general and administrative

    557,872

    481,871

    451,421

    Amortization of in-licensed rights

    2,405

    1,559

    714

    Total cost and expenses

    1,683,898

    1,511,160

    1,469,214

    Operating income (loss)

    218,081

    (267,824
    )

    (536,201
    )

    Other income (loss), net:

    Other